glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Frontiers | Research progress of

10.1038/s44324-024-00030-5 6

Until recently, the only effective treatment for obesity was bariatric surgery, and a century of drug development for obesity can be essentially described as a failure until now

Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By Geography Western Europe Eastern Europe Nordic Region Mediterranean Region Based on Geography, the Europe insulin drugs, and GLP-1 receptor agonist market is segmented into Western Europe, Eastern Europe, the Nordic Region, and the Mediterranean Region

For patients currently on basal insulin or a GLP-1 RA : Start at 16 units subcutaneously once daily without regard to meals

Anti-inflammatory and Antifibrotic Effects Chronic inflammation and myocardial fibrosis are hallmarks of HF progression

The drug is in the same class of GLP-1 medications as Ozempic, Wegovy, Mounjaro, and Zepbound weekly injections that upended the weight-loss industry but in pill form